Amorphous poly(D,L-lactide) coating
First Claim
1. A coating comprising an amorphous poly(D,L-lactide) (PDLLA) having a degree of crystallinity of 10% or below and an additional biocompatible polymer,wherein the PDLLA is not made from a 50/50 blend of L,L-lactide and D,D-lactide,wherein the amorphous PDLLA is poly(meso-D,L-lactide) (meso-DLPLA), racemic poly(D,L-lactide) (racemic-DLPLA), or combination thereof,wherein the coating further comprises a syndiotactic polylactide (LPLA),and wherein the additional biocompatible polymer is selected from the group consisting of polymers and copolymers of 3-hydroxypropanoate, 3-hydroxyhexanoate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 4-hydroxyhexanote, 4-hydroxyheptanoate, and 4-hydroxyoctanoate;
- poly(tyrosine carbonates);
poly(tyrosine ester);
polyphosphoester;
polyphosphoester urethane;
polycyanoacrylates;
poly(vinylidene fluoride-co-hexafluoropropylene);
cellulose butyrate;
phosphoryl choline;
poly(aspirin);
polymers and co-polymers of alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA);
poly(styrene-isoprene-styrene)-PEG (SIS-PEG);
polystyrene-PEG;
polyisobutylene-PEG;
polycaprolactone-PEG (PCL-PEG);
poly(methyl methacrylate)-PEG (PMMA-PEG);
polydimethylsiloxane-co-PEG (PDMS-PEG);
polypropylene oxide-co-polyethylene glycol;
poly(tetramethylene glycol);
hydroxy functional poly(vinyl pyrrolidone); and
combinations thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Implantable devices formed of or coated with a material that includes an amorphous poly(D,L-lactide) formed of a starting material such as meso-D,L-lactide are provided. The implantable device can be used for the treatment, mitigation, prevention, or inhibition of a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
-
Citations
24 Claims
-
1. A coating comprising an amorphous poly(D,L-lactide) (PDLLA) having a degree of crystallinity of 10% or below and an additional biocompatible polymer,
wherein the PDLLA is not made from a 50/50 blend of L,L-lactide and D,D-lactide, wherein the amorphous PDLLA is poly(meso-D,L-lactide) (meso-DLPLA), racemic poly(D,L-lactide) (racemic-DLPLA), or combination thereof, wherein the coating further comprises a syndiotactic polylactide (LPLA), and wherein the additional biocompatible polymer is selected from the group consisting of polymers and copolymers of 3-hydroxypropanoate, 3-hydroxyhexanoate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 4-hydroxyhexanote, 4-hydroxyheptanoate, and 4-hydroxyoctanoate; - poly(tyrosine carbonates);
poly(tyrosine ester);
polyphosphoester;
polyphosphoester urethane;
polycyanoacrylates;
poly(vinylidene fluoride-co-hexafluoropropylene);
cellulose butyrate;
phosphoryl choline;
poly(aspirin);
polymers and co-polymers of alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA);
poly(styrene-isoprene-styrene)-PEG (SIS-PEG);
polystyrene-PEG;
polyisobutylene-PEG;
polycaprolactone-PEG (PCL-PEG);
poly(methyl methacrylate)-PEG (PMMA-PEG);
polydimethylsiloxane-co-PEG (PDMS-PEG);
polypropylene oxide-co-polyethylene glycol;
poly(tetramethylene glycol);
hydroxy functional poly(vinyl pyrrolidone); and
combinations thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 21, 22, 23, 24)
- poly(tyrosine carbonates);
-
13. An absorbable stent formed of a material comprising an amorphous poly(D,L-lactide) (PDLLA) having a degree of crystallinity of about or below 10% and an additional biocompatible polymer,
wherein the PDLLA is not made from a 50/50 blend of L,L-lactide and D,D-lactide, wherein the amorphous PDLLA is poly(meso-D,L-lactide) (meso-DLPLA), racemic poly(D,L-lactide) (racemic-DLPLA), or combination thereof, wherein the material further comprises a syndiotactic polylactide (LPLA), and wherein the additional biocompatible polymer is selected from the group consisting of polymers and copolymers of 3-hydroxypropanoate, 3-hydroxyhexanoate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 4-hydroxyhexanote, 4-hydroxyheptanoate, and 4-hydroxyoctanoate; - poly(tyrosine carbonates);
poly(tyrosine ester);
polyphosphoester;
polyphosphoester urethane;
polycyanoacrylates;
poly(vinylidene fluoride-co-hexafluoropropylene);
cellulose butyrate;
phosphoryl choline;
poly(aspirin);
polymers and co-polymers of alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA);
poly(styrene-isoprene-styrene)-PEG (SIS-PEG);
polystyrene-PEG;
polyisobutylene-PEG;
polycaprolactone-PEG (PCL-PEG);
poly(methyl methacrylate)-PEG (PMMA-PEG);
polydimethylsiloxane-co-PEG (PDMS-PEG);
polypropylene oxide-co-polyethylene glycol;
poly(tetramethylene glycol);
hydroxy functional poly(vinyl pyrrolidone); and
combinations thereof. - View Dependent Claims (14, 15, 17)
- poly(tyrosine carbonates);
-
18. An implantable device comprising a coating that comprises:
alternating layers comprising meso-DLPLA and comprising racemic-DLPLA;
wherein one layer is a primer layer consisting of meso-DLPLA and a syndiotactic polylactide (LPLA).
-
19. An implantable device comprising a coating that comprises:
alternating layers comprising meso-DLPLA and comprising syndiotactic polylactide (LPLA);
wherein one layer is a primer layer consisting of meso-DLPLA and a syndiotactic polylactide (LPLA).
Specification